T portance for the diagnosis and management of patients with neonatal alloimmune thrombocytopenic purpura (NATP), posttransfusion purpura (PTP), and some patients with platelet transfusion refractoriness (for a review, see Newman et all and Newman and Valentin'). The molecular bases for at least eight different platelet-specific alloantigenic epitopes involved in these immunological disorders have now been making it possible to perform DNAbased genotyping for the most clinically significant human platelet alloantigens using a variety of cellular sources, without the dependence on platelets. Because of the limitations associated with previously employed serological typing techniques, an increasing number of laboratories are turning to DNA-based genotyping as their main technique for platelet alloantigen determination.
Several approaches are currently used for platelet genotyping, all based on the polymerase chain reaction (PCR). Although restriction fragment length polymorphism (RFLP) analysis of restriction endonuclease digested PCR products spanning the polymorphic and allele-specific oligonucleotide (ASO) hybridization a n a l y s i~~,~~, "
were among the first techniques adopted, a variety of more efficient alternative approaches, including allele-specific PCRI4,lS have been employed more recently.
Glanzmann thrombasthenia (GT) is a rare, inherited, autosomal recessive bleeding disorder that is characterized by mucocutaneous bleeding and the failure of platelets to bind fibrinogen and aggregate following stimulation by physiologic agonists (for a review, see Newman et all6). The molecular abnormalities in GT patients affect the genes encoding membrane glycoproteins (GP) IIb and GPIIIa, and have been found to range from major deletions and inversions to single point mutations 16. The nature of the genetic defect in most cases of GT leads to the failure of the GPIIb-IIIa complex to be expressed on the platelet surface, though variant forms of GT have been reported in which nonfunctional forms of GPIIb-IIIa are expressed at normal or near-normal levels.
In this report, we describe a molecular integrin defect Phenotypic and genotypic analysis of human platelet alloantigens. Platelets were isolated from EDTA-anticoagulated blood, and the PIAi/PIAZ phenotypes were determined serologically using a modified antigen-capture enzyme-linked immunosorbent assay (MACE), as previously described." Genotypic analysis of human platelet alloantigens was performed using allele-specific oligonucleotide hybridization using standard methods.'* Briefly, genomic DNA was isolated from peripheral blood leukocytes of sodium-EDTA anticoagulated blood by standard proteinase K treatment followed by salting out of protein with super saturated NaCI, precipitation of DNA with absolute ethanol, and spooling." Following PCR amplification of the GPIIIa gene in the region encompassing the PIA polymorphism,' 100 ng amplified DNA was applied to MagnaGraph nylon transfer membranes (MSI, Westboro, MA) using a dot-blot apparatus (Fisher Scientific Corp, Itasca, IL) and hybridized with each of two 13-mer oligonucleotide probes differing only at the central base specific for the platelet allotype sequences (TIq6 = PIA1, C,96 = PIA2) Samples from individuals with known PIA genotypes were included as controls. The oligonucleotide probes were end-labeled with digoxigenin-1 1 -deoxyuridine-triphosphate, and were immunologically detected using alkaline phosphatase-conjugated polyclonal sheep antidigoxigenin Fab fragments (Boehringer Mannheim, Indianapolis, IN). Antibody conjugates were detected using the nitro blue tetrazoliud5-bromo-4-chloro-3-indolyl phosphate substrate pair. In selected cases, platelet genotyping was also performed using allele-specific PCR amplification, as previously described.'' Electrophoresis in 1.6% agarose containing 0.5 pg/mL ethidium bromide with ultraviolet (UV) light illumination was performed to visualize allele-specific amplification products.
The murine monoclonal IgG, antibody, AP3, which is specific for GPIIIa,I9 was isolated from ascites fluid using Protein A-Sepharose. AP3 (100 pg) was iodinated with 1 mCi of carrier-free Na'251 (New England Nuclear, Boston, MA) using insolubilized lactoperoxidase (Enzymobeads, BioRad Laboratories) according to the manufacturer's directions. Unbound '''1 was removed by gel filtration through Sephadex G-25 equilibrated in phosphate-buffered saline (PBS), pH 7.0. The specific activity of the AP3 used in binding assays was approximately 5,100 cpm/ng protein.
The iodinated protein was stored at 4°C until use.
Binding assays were performed in triplicate at room temperature using platelet rich plasma (PRP) prepared from whole blood anticoagulated with acid-citrate-dextrose, as previously described." Varying concentrations of radiolabeled AP3, diluted into platelet poor plasma (PPP), were added to PRP such that the final platelet concentration was 1 X IO'/mL and the final volume 300 pL. After incubation for 60 minutes at 37"C, a 150-pL aliquot was layered onto 500 pL of 20% sucrose dissolved in 20 mmol/L Tris, 150 mmoW NaCl pH 7.4, and centrifuged at 12,OOOg for two minutes. After removing the supernatant, centrifuge tube tips were amputated and the bound radioactivity determined in a gamma counter. Total radioactivity was determined by counting an identical 100 pL aliquot of each reaction mixture. Nonspecific binding was determined in parallel tubes in the presence of a 250-fold excess of unlabeled AP3. This value, which was typically less than 2%, was subtracted from the total bound cpm to yield specifically bound cpm.
Genomic DNA was prepared from whole blood using the procedure of Poncz et al.'" A 20-pg aliquot was digested at 37°C with 30 to SO U of the restriction endonucleases Radioiodination of AP3.
Binding isotherm analysis.
Southern blot analysis. EcoRI, Sac I, and Xba I using buffers and conditions recommended by the suppliers. Fragments were separated by electrophoresis through 0.6% agarose and transferred to a Gene Screen Plus membrane (New England Nuclear, Boston, MA). Hybridization and washing were performed at 65°C. A full-length GPIIIa cDNA was used as probe for the genomic Southern blot analysis. The probe was radiolabeled with aZZP-dCTP using random hexamers and the Klenow fragment of DNA polymerase using standard methods."
Thirteen sets of primers flanking all 14 exons of the GPIIIa gene were constructed based on the published genomic sequence."^" Exons 6 and 7 were amplified as one product. In each reaction of SO pL, 500 ng of genomic DNA was used. Following an initial preheating step at 94T, PCR amplification was performed for 30 cycles using a protocol of denaturation at 94°C for I minute, annealing at 58°C for 2 minutes, and extension at 72°C for I minute. After the final cycle, the sample was kept at 72°C for I O minutes and then stored at 4°C until use. PCR-amplified DNA corresponding to exons I -14 of GPIIIa was gel purified (Geneclean; Dianova) and used as template for automated sequencing (Applied Biosystems). In some instances, PCR products were also subcloned into the plasmid vector pGEM5 (Promega Corp, Madison, WI) and the inserts sequenced by the dideoxy chain termination method, using Sequenase T7 DNA polymerase (US Biochemical Corp, Cleveland, OH).
DNA sequence analysis of the GPIIIa gene.
RESULTS
Since the inception of DNA-based genotyping for human platelet alloantigen polymorphisms, more than 7 years ago,' more than 1,000 patients have been DNA typed and the results correlated with those obtained using traditional serological methods (McFarland and Newman, unpublished data, April 1996). To date, the overwhelming majority of samples have yielded identical results using either technique, ie, the phenotypes and genotypes were concordant. Rarely, however, genotypic analysis shows the presence of an allelic form of a platelet membrane glycoprotein that is not detected on the platelet surface using well-characterized human alloantisera of defined specificity. To better understand the reasons for these occasional discrepancies, we examined in more detail the molecular basis in one such patient, P.D.J.
As shown in Table 1 , platelets from patient P.D.J. strongly expressed on their surface the PIA' alloantigenic determinant, whereas anti-PlA2 antisera failed to bind, consistent with P.D.J. being homozygous for the PIA' allelic form of GPIIIa. In contrast, both allele-specific oligonucleotide hybridization analysis (data not shown). as well as sequence-specific PCR primer analysis (Fig 1 ) clearly demonstrated that patient P.D.J. carries both the PI"' and PI"' alleles of GPllla, ie. is heterozygous for PI". Based on these results. we hypothesized that the P.D.J. had inherited a silent PI'" allele, effectively making him a carrier for type I Glanzmann thrombasthenia.
Platelets from type 1 Glanzmann heterozygotes typically express on their surface approximately SO% to 60%-of normal levels of the GP1Ib-IlIa complex." To determine whether P.D.J. platelets express reduced levels of surface GPIIb-IIIa, ''51-AP3 binding studies were performed using methods that have been previously described." As shown in Fig 2, whereas control platelets bound 45 ng APYS X IOh platelets at saturation (corresponding to approximately 50.000 GPIIb-Illa complexes/platelet), P.D.J. platelets bound only 20 ng of AP3/S X IO" platelets at saturation. which corresponds to approximately 20.000 GPIlb-llla complexes/platelet. The observation that P.D.J.'s platelets express only half the number of GPIlb-IIIa complexes on their surface is consistent with the notion that P.D.J. is a carrier of a defective GPlIIa allele that ( I ) encodes a C at nucleotide 196 (and therefore genotypes as a PI"' allelic form), and (2) has a molecular defect elsewhere on the gene that prevents its synthesis and/or expression.
To identify the mutation responsible for the putative type I Glanzmann thrombasthenia carrier status in patient P.D.J.. all 14 exons of the GPIIIa gene were PCR-amplified using primers corresponding to the flanking regions of the exons. All PCR products derived from P.D.J. genomic DNA were identical in size to those obtained from the normal control DNA, and genomic Southern blots were normal. as well (data not shown), indicating that the defective allele did not harbor major insertions, deletions, or gene rearrangements. However. direct automated sequence analysis of the PCR products showed a two-base deletion (nucleotides 728 and 729 of GPIIIa cDNA) within exon 4 (data not shown). To confirm this observation, the PCR product containing exon 4 was subcloned into pGEMS. and individual clones subjected to manual DNA sequence analysis. The sequence of For 18 different clones was determined. with approximately 50% of them containing the dinucleotide deletion within the codons for GPlIla amino acids 210 and 21 1 (Fig 3) . This frameshift results in a change in the sequence of amino acids 21 1-223 and. more importantly creates a stop codon 38 nucleotides downstream. yielding ;I truncated protein that would, if fully transcribed and translated, contain only the first 223 of 762 total amino acids normally present in mature. wild-type GPllla. Thus. P.D.J. is a carrier for type I Glanzmann thrombasthenia. having one normal GPIIla allele that encodes the PI"' alloantigenic determinant, as well as a PI"' allele of GPllla that is not expressed on the cell surface.
DISCUSSION
The human platelet plasma membrane contains over 100 proteins that can be recognized hiochemically as individual discrete spots on two-dimensional sodium dodecyl sulfate (SDS) polyacrylamide gels. During the past 20 years, the biochemical basis for platelet function has advanced greatly as the structures and functions for many of these membrane components have been solved at the molecular level. With the realization that platelet membrane glycoproteins control crucial platelet functions such as platelet activation. adhesion to sites of vessel wall damage. aggregation. and clot retraction, we have also come to appreciate that many of these same glycoprotein receptors are polymorphic within the human gene pool, that is. there exist two or more functional allelic forms. The clinical consequences of these molecular variations are not unlike that found in other cellular and organ systems. in that these polymorphisms can be and are recognized as immunologic targets in a transplant settingbroadly defined. Such settings can include organ transplantation, blood transfusion. and pregnancy.
The first indications that the platelet surface was polymorphic appeared in the late 1950s and early 1960s. when alloantibodies that developed in patients with PTP and NATP were shown to discriminate antigen-positive from antigen-nega- tive platelets.2J-'X Since that time, serological studies have continued to provide important population frequency data for the currently recognized human platelet antigenic epitopes. which now number more than eight.' Recent advances in molecular and cellular biology. however. have made it possible to build upon previous serologic and biochemical studies of human platelet alloantigen systems in important and exciting ways. In addition to providing a detailed basic understanding of the polymorphisms that are responsible for eliciting an nlloimmune response to the platelet surface, the molecular biologic characterization of platelet membrane glycoprotein polymorphisms has enabled the development of DNA-based typing for the platelet alloantigenic epitopes, which in turn has markedly improved our ability to diagnose and manage platelet :tlloimmune disorders.
A variety of molecular diagnostic methods have been adopted for the determination of platelet alloantigen genotypes. including KFLP-based approaches,',' ' allele-specific oligonucleotide hybridization and PCR reactions that employ sequence-specific PCR primers.'"," Each of these techniques offers significant advantages over serologically-based methods, which rely on the use of ( I ) human alloantisera. which are often available in only limited quantities in specialized centers. and ( 2 ) patient platelets. which are often difficult to obtain in siifficicnt quantities from patients who are often thrombocytopenic. Nonetheless, serological methods remain the only way to determine whether or not individuals have produced an antiplatelet alloantibody. and are still the most frequently used way to determine the antigenic composition of the platelet surface.
Despite the fact that genotypic and phenotypic analysis of platelet alloantigenic epitopes almost always yield identical results. we and others have noted rare circumstances in which discordant results have been obtained. A number of explanations have been offered for such discrepant findings, including the postulated presence of rare. allelic variants of existing human platelet alloantigenic epitopes (for example, For personal use only. on October 27, 2017. by guest www.bloodjournal.org From a third allele of the PIA system [PlA3?]) caused by yet-to-bedescribed mutations at or near amino acid 33 of GPIIIa) that could interfere with current DNA typing methods. The purpose of the present investigation was to investigate whether a simpler explanation might be found in those cases in which phenotyping and genotyping do not agree.
One such example was provided by patient P.D.J., who serologically phenotyped as a PIA1'A1 homozygous individual (Table l ) , but who very clearly carried both the PIA1 as well as the PlA2 allele of GPIIIa upon genotypic analysis (Fig 1) . Because the PlA2 allelic form of GPIIIa was not detectable using serological methods, we postulated that this allele harbored a mutation that prevented its expression, a hypothesis that was bome out by quantitating the amount of GPIIIa on the platelet surface (Fig 2) , and by our finding a dinucleotide deletion in this allele that results in the production of a truncated protein (Fig 3) . Thus, the PlA2 allele of GPIIIa in this individual is able to be detected only by genotypic analysis, because it is silent at the protein level.
In conclusion, while encountered only rarely, carriers of Glanzmann thrombasthenia (GPIIb or GPIIIa mutations) or Bernard Soulier (GPIba, GPIbP, GPV, or GPIX mutations) alleles that are at the same time heterozygous for human platelet alloantigenic epitopes carried on these same glycoproteins, have the possibility to give discrepant results when comparing genotypic versus phenotypic typing results. Clearly, the combination of serologic and DNA-based evaluation contributes complementary and beneficial diagnostic information than either one alone are able to provide. In light of these findings, it is probably not necessary to invoke more complicated explanations for discordant DNA typing versus serologic typing results. Recently proposed rare third allelic variants for human platelet alloantigen systems are unlikely to be borne out.
